drugset
drugset / Trial / NCT04589741

Toripalimab Combined With CAV/IE Regimen

NCT04589741 ↗

Phase 2 Recruiting 134 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study was to investigate the efficacy and safety of CAV/IE chemotherapy combined with toripalimab versus CAV/IE chemotherapy alone in the treatment of patients with advanced or unresectable bone and soft tissue sarcomas who failed in standard treatment.

Timeline

Start
2020-10-23
Primary completion
2027-01-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background ADM Unknown 50 mg/m2 Intravenous
Background CTX Unknown 1.2 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 35 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 40 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Etoposide Small molecule 90 mg/m2 Intravenous
Background IFO Unknown 1.5 g Intravenous
Background VCR Unknown 1.4 mg/m2 Intravenous

Indications

soft tissue sarcoma